Furthermore, pembrolizumab, in particular, incorporates the screening of biomarkers, such as PD-L1 expression levels and tumor mutation burden, to identify patient populations most likely to benefit, thereby facilitating a more precise therapeutic approach (43). The gene discussed is CD274; the disease is neoplasm.